Drug Profile
Fluoxetine - Herantis Pharma
Alternative Names: HER-801Latest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator Hermo Pharma
- Developer Herantis Pharma
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Eye disorder therapies; Propylamines; Small molecules
- Mechanism of Action Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 06 Aug 2014 No development reported - Phase-II for Amblyopia (in adults) in Finland and Estonia (PO)
- 27 May 2013 Hermo Pharma completes a phase II trial in Amblyopia (in adults) in Estonia and Finland (EudraCT2010-023216-14)
- 14 Nov 2012 Hermo Pharma completes enrolment in its phase IIa trial for Amblyopia (in adults) in Finland and Estonia